Cytek Biosciences, Inc.
CTKB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $431,576 | $514,639 | $838,546 |
| - Cash | $93,281 | $75,470 | $95,298 | $98,716 |
| + Debt | $22,307 | $14,119 | $15,897 | $17,016 |
| Enterprise Value | – | $370,225 | $435,238 | $756,846 |
| Revenue | $52,293 | $45,602 | $41,457 | $57,476 |
| % Growth | 14.7% | 10% | -27.9% | – |
| Gross Profit | $27,551 | $23,867 | $20,157 | $33,652 |
| % Margin | 52.7% | 52.3% | 48.6% | 58.5% |
| EBITDA | -$4,215 | -$3,373 | -$8,091 | -$2,453 |
| % Margin | -8.1% | -7.4% | -19.5% | -4.3% |
| Net Income | -$5,478 | -$5,583 | -$11,402 | $9,643 |
| % Margin | -10.5% | -12.2% | -27.5% | 16.8% |
| EPS Diluted | -0.04 | -0.044 | -0.09 | 0.073 |
| % Growth | 9.1% | 51.1% | -224% | – |
| Operating Cash Flow | -$3,898 | $108 | -$125 | $1,997 |
| Capital Expenditures | -$655 | -$1,577 | -$851 | -$903 |
| Free Cash Flow | -$4,553 | -$1,469 | -$976 | $1,094 |